Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

April 21, 2022

New York Stock Exchange US Consumer Staples Tobacco earnings 80 min

Earnings Call Speaker Segments

Nick Rolli

executive
#1

Good day, and thanks for being with us. We put out a press release earlier today with full details about the results for our first quarter of 2022. That release is available at www.pmi.com. You'll find a glossary of terms — among them the definition of reduced-risk products, or RRPs — along with adjustments, other calculations, reconciliations to the most directly comparable U.S. GAAP measures, and extra heated tobacco unit market data at the back of today's webcast slides, which are up on our website. Except where noted otherwise, whenever we mention IQOS, we mean our IQOS heat-not-burn products, and whenever we mention smoke-free products, we mean our RRPs. The growth rates we show on an organic basis reflect adjusted results that are currency-neutral and exclude acquisitions. Any figures and comparisons given on a pro forma basis leave out PMI's operations in Russia and Ukraine entirely. During the third quarter of 2021, we bought Fertin Pharma, Vectura Group and OtiTopic. We launched a new Wellness and Healthcare business, Vectura Fertin Pharma, on March 31, 2022, bringing these entities together. Results from operations for this new business appear in the Other category. Our Wellness and Healthcare business's operations are managed and evaluated apart from the geographical segments. Remarks today include forward-looking statements and projections of future results. Please turn your attention to the Forward-Looking and Cautionary Statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. I'm now delighted to introduce Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer. Jacek, the floor is yours.

Jacek Olczak

executive
#2

Thanks, Nick, and hello everybody. I want to start by wishing all of you safety and good health. The past several months have been very difficult for a great many of us because of the heartbreaking developments surrounding the conflict in Ukraine. I want to voice our grief and our backing for the Ukrainian people. What matters most to us is our staff and their loved ones, and we've been doing all within our power to help them, guided by three priorities. The first is getting our people out — we've moved more than 1,000 employees and relatives out of the nation and helped over 2,700 additional people relocate from areas of fighting to places farther from the worst of the combat. The second is getting urgently needed supplies to those who are unable to depart or who have chosen to stay in Ukraine. And the third is giving shelter, quick help and a way ahead to those who have exited the nation; beyond that, we've already given roughly $10 million in money and provided necessary goods throughout the country, both straight to humanitarian groups and via our employee-run program, Projects With a Heart. That covers supplying medicine, food, clothing and many other things to our coworkers and to the wider public, buying 25 ambulances and establishing a mobile hospital. Given what we can currently see, we project an extra expense of approximately $25 million for further assistance to employees during this year. Our coworkers in bordering nations keep offering crucial help to all those coming from Ukraine in search of safety. We extend our deep thanks to all who are part of these kind efforts to assist in such a hard period. Turning to how this affects our business operations, output at our Ukraine manufacturing site in Kharkiv is still halted. Although commercial activity in Eastern Ukraine has largely been hit very hard, we've observed a degree of restarting in places where circumstances permit, as we try to make the most of product availability and service to consumers by drawing on inventories we already hold. We're also making plans now to bring in products from other manufacturing sites, even though this could mean greater expenses. We keep paying wages to every one of our Ukrainian employees and giving significant in-kind aid to them and their families. As we said in our March 24 press release, PMI's board of directors and senior executive team are exploring ways to leave the Russian market in a systematic fashion amid a complicated and fast-shifting regulatory and operating landscape. Given the complicated laws that have just been enacted, this is far from simple, yet we remain dedicated to finding a workable route out of the market while assisting our staff in Russia during this time; it is equally evident that normal operations cannot go on because of regulatory and supply chain upheaval, which already affected the Russian business during Q1; we have implemented specific measures to reduce our operations, for example canceling every new investment and product launch, among them IQOS ILUMA and IQOS VEEV; we are removing 25% of our cigarette products from sale, among them Marlboro and Parliament SKUs. In addition, we have scrapped the $150 million investment in capacity meant to eventually produce over 20 billion TEREA sticks for IQOS ILUMA at our Russian factory. Obviously, the conflict's effects have also caused turmoil in worldwide supply chains and worsened inflationary strain on particular materials and services. Even so, Q1 results and the projection for our business outside Russia and Ukraine stay robust; on a reported basis, our outlook takes the conservative assumption of no additional contribution from Russia or Ukraine starting April 1. To offer a consistent picture, because of the unpredictability and instability of these two markets, we will now likewise present adjusted results and guidance on a pro forma basis that excludes Russia and Ukraine from both the prior and the entire current year. I will now pass things to Emmanuel, who will go through this in greater detail.

Emmanuel Babeau

executive
#3

Thanks, Jacek. We turned in a really strong Q1, posting double-digit organic net revenue growth along with currency-neutral adjusted diluted EPS growth on a pro forma basis, which leaves Russia and Ukraine out of both the current quarter and the comparable period last year. Currency-neutral results overall also came in above what we had expected. IQOS had an outstanding quarter, and the reacceleration we saw last quarter kept going as device supply constraints kept loosening. Our IQOS user count increased by over 1 million, again excluding Russia and Ukraine, which is a very strong result. RRP pro forma net revenues rose 23%, and pro forma smoke-free net revenues made up more than 30% of the whole company. Just as important, pro forma HTU shipment volumes were up 18% versus the same quarter a year ago. That shows great progress in the EU Region, ongoing expansion in Japan, and growth above 50% in low and middle income markets. In markets where IQOS is available, PMI HTUs now rank as the number two nicotine brand, since our work on innovation, portfolio and geographic expansion is fueling consumer trial and adoption. IQOS ILUMA's impressive start is continuing in Japan and Switzerland, and early take-up in Spain, our newest launch market, is very encouraging. Success out of the gate in these three quite different markets reinforces how confident we are that ILUMA will be an exciting growth driver for us going forward. At the same time, our combustible business turned in a robust performance, beating our goal of stable category share and generating positive volume and organic net revenue growth. Beyond helping our strong financial results, this also strengthens our capacity to maximize how many adult smokers switch to smoke-free alternatives. All told, our business has begun the year well, and although currency works against us in 2022, we still expect to deliver another year of robust organic growth on both the top and bottom lines. Now to the headline numbers: our Q1 net revenues rose organically 9% overall and 10% on a pro forma basis. That mirrors total volume growth, which came from IQOS's underlying strength, the continued rebound of the combustible business in many markets against a pandemic-affected comparison, and some favorable timing effects, including inventory movements. Total organic net revenue per unit was up 5.3%, or 4.9% on a pro forma basis, thanks to a bigger share of IQOS HTUs in our sales mix, more device volumes, and pricing. Combustible pricing beat expectations, at 2.9% pro forma, or roughly 6% when Indonesia is also excluded. Our total Q1 adjusted operating income margin fell organically 30 basis points, and 40 basis points excluding Russia and Ukraine. That stems from a lower gross margin against a tough prior year comparison in which productivity was higher, largely because of timing factors. As we noted in our full year earnings, Q1 margins took a hit from higher device sales tied to growing IQOS user acquisition, channel replenishment and IQOS ILUMA. Like I said earlier, the per-unit expense and the weight for ILUMA refills, along with what the device costs, start out on the high side while we scale production, and we anticipate that getting better starting next year. On top of that, price pressures across some parts of our supply chain — energy, pay, and direct materials — plus more reliance on shipping by air, were made worse because of the war in Ukraine. Even with those short-term pressures on margin, the benefits came through from IQOS getting bigger, from our pricing, and from cost savings, all working together with the solid growth in our net revenue. That let us post adjusted diluted EPS of $1.56, which included a currency headwind of $0.23, and that works out to plus 14% growth in currency-neutral terms. That came in well above what we had expected on a currency-neutral basis, even once you factor in roughly $0.06 of timing gains. If you set aside Russia and Ukraine, our pro forma adjusted diluted EPS came to $1.46, up plus 16%. Now let's move to what we expect for 2022. As Jacek said, because we can't see clearly what will happen in Russia and Ukraine, we're giving an adjusted outlook on a pro forma basis that leaves out those two markets for the whole year; with our underlying business picking up speed again, the fundamentals behind our growth stay solid. The key point is that we anticipate organic net revenue growth of plus 4.5% to plus 6.5%, measured against 2021 pro forma adjusted net revenues of $29.2 billion. That sits above the trajectory we had forecast before for total PMI, even though there's a drag of roughly half a point from moving to hyperinflationary accounting in Turkey. Built into that range is the risk that supply chain disruption hits certain materials, a somewhat slower build-up of TEREA production capacity caused by the production cancellation in Russia, some of which had been meant for export, the continued uncertainty around whether devices will be fully available, and how quickly the pandemic recovery proceeds; for the full year, we expect our pro forma adjusted operating income margin to come in organically flat to plus 100 basis points higher. As we said at full year results, a lower gross margin is expected as we put money into new innovations and face temporarily higher unit and transportation costs tied to ILUMA's rapid growth. Since that time, we've seen inflation climb for raw materials and energy, plus extra supply chain expenses from war-related disruptions, among them a temporary rise in air freight for both HTUs and certain cigarette products. Stronger device sales than expected thanks to the huge uptake of IQOS ILUMA, along with device supply constraints easing, also dilute margin at first. Even with these added headwinds, and with COGS now expected to rise by about $300 million more than we originally thought, we're still confident we'll reach organic pro forma margin expansion, since our robust revenue growth, favorable product mix, and cost savings initiatives will produce sustainable accretion. We project pro forma currency-neutral adjusted diluted EPS growth of plus 9% to plus 11%, which is likewise above our earlier full year guidance for total PMI. That works out to a pro forma adjusted diluted EPS range of $5.35 to $5.46, and that includes an estimated currency headwind of roughly $0.63 at the rates in effect now. When you set that against the adjusted diluted EPS guidance for 2022 we gave back in February — $6.12 to $6.30 — the gap mainly comes from leaving Russia and Ukraine out of the picture, plus an added currency headwind. Our outlook for underlying IQOS growth is still very strong. Looking at it on a pro forma basis, we're aiming to ship between 88 billion and 92 billion HTU units, which works out to growth of plus 20% to plus 25% against the pro forma prior year figure of 73.5 billion units. That leaves out the roughly 5 billion units that went to Russia and Ukraine during Q1, and since we're taking the cautious view that nothing more comes from those markets starting April 1, the full-year outlook comes to 93 billion to 97 billion units; for the year, we still anticipate pro forma HTU shipments running slightly above IMS, following a second-quarter period where they fell short, which I'll get into later. Today's release lays out several additional assumptions that sit behind our outlook. Excluding Russia, Ukraine, the U.S. and China, we see combined industry cigarette and HTU volume falling by as much as minus 1%. Because we lead in smoke-free products, because the category is growing structurally and takes up a rising share of our business, and because our combustible share is steadying, we anticipate picking up share.

Emmanuel Babeau

executive
#4

So we're aiming for total PMI pro forma shipment volumes that are positive, in a range from flat up to plus 1%. For full year combustible pro forma pricing, we're assuming roughly plus 3%, and that now includes the negative effect from hyperinflationary accounting in Turkey. Pricing conditions are getting better, Indonesia included, though there are still difficulties because of continuing pandemic-related effects and pressure on disposable income. Among our other assumptions, we've got about $10 billion in operating cash flow and an effective tax rate between 21% and 22%; full-year capital expenditures we still expect to be approximately $1 billion. Even with the war in Ukraine weighing on us, our balance sheet is in good shape, and we stay firmly dedicated to giving cash back to shareholders via dividends and opportunistic share repurchases. Turning to how pro forma performance is phased across this year, we anticipate a strong H1 overall, while margin expansion and adjusted diluted EPS growth will be weighted toward the second half. This mostly mirrors IQOS reaccelerating as device supply constraints let up, with device volumes recovering sharply as we rebuild channel inventories for user acquisition and serve the quicker ILUMA replacement cycle in Japan. On top of that, our average device price sits below the prior year, which mirrors stepped-up commercial activities aimed at driving acquisition, among them widening our device portfolio with LIL and ILUMA ONE. Although our devices remain priced at a significant premium to heavily discounted competitive offerings, we've already seen encouraging signs that our high category share is stabilizing. Beyond that, as we adapt our supply chain flows to the global disruptions currently affecting various materials and logistic services, together with the effects of the war in Ukraine, there could be a risk of brief out-of-stock situations for certain cigarette SKUs in select markets, and we're adjusting some products to reflect what specific materials are available. Reorganizing supply chain flows will add to the later timing of shipments into certain markets. In particular, we expect Q2 to take a hit from a number of temporary or specific factors, among them the reversal of certain Q1 timing benefits. Organic pro forma net revenue growth should be low single-digit, with other notable factors being the delayed timing of HTU and cigarette shipments to Japan, which creates an approximate 2 point drag on growth, plus a further effect from the shift to hyperinflationary accounting in Turkey, where the Q2 exchange rate comparison is accentuated. For Q2, we expect total PMI pro forma HTU shipments of roughly 20 billion, partly reflecting about 3 billion fewer HTU shipments to Japan than we'd originally planned. That's against 18.7 billion pro forma in Q2, 2021. We expect those 3 billion units to shift into H2, creating an additional growth acceleration in the third and fourth quarters. As for Q2 pro forma operating margins, the disproportionate impact of the catchup in device shipments will come alongside a matching step-up in commercial investments as we support IQOS user acquisition reaccelerating over the coming quarters. Alongside the drag from an unfavorable product mix due to reduced volumes shipped into Japan, the largest quarterly jump we anticipate in air freight expenses — exceeding $80 million — plus additional costs tied to supply chain adjustments, we foresee a further squeeze on margins, prior to a meaningful rebound during the second half. Those forces are captured in our guidance for H1 pro forma adjusted diluted EPS of $2.65 to $2.70, which incorporates a $0.36 adverse currency effect at current exchange rates. That equates to growth of 5% to 7% on a currency-neutral basis against $2.86 a year earlier; paired with our robust first quarter, H1 pro forma top line results should produce organic growth of 5% to 7% in total. During H2, the potent levers of pricing, scale and efficiencies, together with the fading of transitory cost headwinds, ought to surpass inflationary pressure and yield robust top line expansion, organic margin improvement and faster bottom-line growth. Our solid 2022 guidance keeps us squarely on course to hit our 2021, 2023 CAGR objectives on a pro forma basis — above 5% for organic net revenue growth and above 9% for currency-neutral adjusted diluted EPS growth. We continue to expect delivery of roughly $2 billion in gross cost savings by 2023, a point of particular importance amid worldwide inflationary pressure. Crucially, our goal of turning into a majority smoke-free business by net revenues in 2025 is still unchanged. Our confidence in the swift tempo of our transformation endures. Returning to our Q1 results, total shipment volumes rose 3.5% on a total PMI basis and 4.9% pro forma; that mirrors sustained strong broad based pro forma growth of plus 18.4% as user acquisition picks up speed again following the Q3 2021 supply-driven deceleration; along with a gain of plus 3.2% in pro forma cigarette volumes, mirroring the ongoing rebound of the overall industry and of our category share. Our business's shift toward smoke-free products keeps advancing quickly. Heated tobacco units represented nearly 13% of our total pro forma shipment volumes during the first quarter, versus 11.6% for full year 2021. Our sales mix is likewise changing fast, as we become a majority smoke free company. Smoke-free net revenues accounted for more than 30% of our pro forma total in Q1, against 27.9% for full year 2021. IQOS devices made up about 6% of the $2.1 billion in Q1 RRP pro forma net revenues, mirroring greater year-over-year device volumes as supply constraints loosen and ILUMA delivers a strong performance; we posted organic growth of plus 10% in Q1 pro forma net revenues on shipment volume growth of plus 4.9%. This expansion mirrors the twin engines propelling our top line. The first is pricing, spearheaded by combustibles. The second is the growing mix of regulatory projects within our business at higher net revenue per unit, which keeps generating substantial growth; an ever more potent driver as our transformation speeds up. Let's now shift to what drove our Q1 pro forma OI margin, which fell by 40 basis points. On an organic basis, our pro forma gross margin fell 250 basis points, driven by the items I noted previously. On the other side, pro forma adjusted marketing, administration and research costs came in 210 basis points favorable organically, thanks to favorable operating leverage from IQOS expansion plus effective cost efficiency initiatives. Roughly $180 million of gross cost savings came through during the first quarter, consisting of about $80 million in COGS productivities along with $100 million out of SG&A. That brings the total to more than $1 billion from the beginning of 2021 onward, which is already beyond the halfway mark toward our roughly $2 billion objective for 2021, 2023. This gives us room to put money back into top line growth, and to offset inflationary pressures while still generating solid margin progression. We keep stepping up investment in our commercial programs, digital engine and R&D, together with a range of growth opportunities spanning categories and geographies. As our full year guidance shows, we anticipate operating margin progression strengthening as the year goes on, once temporary headwinds and tough comparisons become less of a factor. Our combustible portfolio delivered a good Q1, posting strong pro forma growth in volumes and organic net revenues.

Emmanuel Babeau

executive
#5

This really shows Indonesia and the Philippines bouncing back further, which backs up what we expect for organic net revenue growth and largely steady volumes in South and Southeast Asia this year. More travel also helped volumes rise in Spain and Duty Free. Our combustible share kept recovering, posting a pro forma increase of 0.4 points in Q1 versus a year earlier; that covers improvement in Japan, Turkey and Duty Free as our portfolio programs pay off and social occasions pick back up, with Marlboro up 0.3 points. Even though that category shrinks over the long run, being the leader in combustibles lets us maximize the shift into smoke-free products, and we still aim for a stable category share over time, even with IQOS cannibalization weighing on it. Turning to our total market share, steady IQOS portfolio gains keep building positive momentum; we achieved pro forma share growth in Q1 as anticipated, with increases in Italy, Duty Free, Egypt, Germany and Poland. PMI HTUs have become the number two nicotine brand wherever they're sold, holding 7.5% share outside Russia and Ukraine; that figure covers the top spot in six markets. Now on IQOS results, we figure roughly 17.9 million IQOS users existed as of March 31, leaving out Russia and Ukraine, which had about 4.8 million users estimated at December 31, 2021. That works out to pro forma growth exceeding 1 million users, an outstanding result by historical measures. The driver was consumer programs restarting across many markets once device supply limits eased, capturing the brand's strong underlying demand, which the extremely impressive IQOS ILUMA launch also demonstrates. We figure 71% of all IQOS users beyond Russia and Ukraine — 12.7 million adult smokers — have switched to IQOS and quit smoking, while the rest are at different stages of conversion; we also felt very encouraged by the FDA's recent MRTP order for IQOS 3, since the entire authorized IQOS lineup is now classified as modified risk tobacco products. Within the EU Region, first quarter HTU share hit 7.6% of combined cigarette and HTU industry volume, a first quarter share gain of 2 points, partly helped by the timing of inventory movements. Adjusted IMS volumes likewise keep showing strong sequential growth, and we look for that to carry into the second quarter, though the combustible market's normal seasonality plus the reversal of Q1 inventory movements should mean a lower sequential share in Q2. This strong result includes solid user and volume growth throughout the region, with particularly notable contributions from Italy and Poland. I'd also like to call out Hungary and Lithuania again, where our Q1 national HTU share came in above 25%. For more detail on how we're doing in the EU Region, this slide presents a selection of the most recent key city offtake shares. Vilnius is still out front, nearing a 40% share, while Budapest, Rome and Athens have all moved solidly into the mid-to-high 20s. Beyond those, we're particularly encouraged by Vienna, which more than doubled to 5%, by the strong momentum in London where share exceeds 6%, and by Zurich accelerating further as ILUMA rolls out; in Japan, our HTU brands' adjusted share rose 1.9 points to a record 22.7% in Q1. That result speaks to the power of our portfolio and to the IQOS ILUMA launch, which is likewise generating impressive gains in Tokyo and other major cities; we look for robust offtake momentum to carry into Q2, when we should reach roughly 24% market share, even allowing for seasonal patterns. On the other side, as I mentioned before, shipment volumes for HTUs in Q2 will probably fall short of last year's level because of supply chain limitations. Since HTU inventories will therefore be drawn down during the second quarter, we anticipate that restocking in H2 will bring a meaningful rebound. Despite this quarter-to-quarter variability, with significant commercial programs lined up and very good underlying momentum, we forecast double-digit HTU shipment volume growth in Japan for the full year, and a strong one at that. Alongside the solid advances in developed markets, IQOS growth looks highly promising in low and middle income countries. Across the 28 such markets launched by December 31, 2021, leaving out Russia and Ukraine, our HTU brands' share climbed 0.8 points year on year to 2.7%. Considering how large these markets are, the premium positioning of the current IQOS portfolio and the fairly early commercialization stage, that is excellent progress. As we said last quarter, we also plan to introduce a new complementary line of heat-not-burn devices and HTUs designed for emerging markets near the end of this year. Egypt is a prime illustration, with offtake exit share in Cairo nearing 5% just 8 months after launch, versus a total Q1 share of 4.3%. Further notable wins include the recently entered market of Morocco, plus Lebanon, Jordan, the Dominican Republic and the Philippines, even with pandemic restrictions in Manila. Turning to IQOS ILUMA, we're happy to report even greater outstanding success since launch, with sales and consumer response continuing to beat our expectations. In Japan, adoption of ILUMA devices and consumables has been swift among existing IQOS users and legal-age smokers alike, with over 30% of the sizable user base up-trading since the August 2021 launch, and more than 20% of sales going to legal-age smokers who are new to IQOS. What's more, the improved and consistently high quality user experience, greater reliability and no cleaning requirement have produced notable observed gains in conversion rates, retention rates and Net Promoter Score. That's a good sign for volumes, since premium-priced TEREA consumables represent the fastest growing launch in the smoke-free category, hitting a 12% offtake share within six months of national launch; surpassing Marlboro Heatsticks and HEETS combined to rank as the number one smoke-free brand. With ILUMA ONE now launched, all three of our IQOS ILUMA devices are available on the market, and that model delivers multiple consecutive uses at lower price points. We're also bringing out a new HTU brand, SENTIA, which works with ILUMA and is being introduced in select prefectures at a mainline price point similar to HEETS. In Switzerland, results have once again been even more impressive, with substantial sales to new users, and after just five months of commercialization TEREA accounts for nearly two-thirds of HTU sales. Our HTU share gain has sped up, going from under 6% in Q3 to 9% in the current quarter, with particularly strong performance across the German-speaking majority of the country. Spain hosted our most recent ILUMA launch last month. Though it's still very early, the indicators are likewise quite positive: device sales to new users are up 50% versus the prior run rate, 10% of existing users upgraded during the first month, and TEREA finished March at more than one quarter of total HTU offtake. Taken across three markets that differ in consumer characteristics and in RRP maturity, these results are plainly very encouraging for the broader roll-out of ILUMA worldwide.

Emmanuel Babeau

executive
#6

Things on the device side are loosening up, but when HTU supply will be ready for additional ILUMA markets has slipped a bit, because the first markets have taken off so quickly that every new market now requires more stock than we had initially planned for. On top of that, ending our TEREA HTU production investment at the Russian plant creates a near-term effect. Because of this, most remaining launches should land near the close of H2. Thanks to ILUMA, IQOS 3 DUO and LIL, the IQOS family now spans three heat-not-burn platforms, letting us address varied consumer preferences and carve the market into segments. Our innovation pipeline across devices and consumables, at multiple price points, looks exciting. Turning to e-vapor, IQOS VEEV keeps delivering encouraging outcomes across its first set of markets. VEEV sits as a premium offering, priced on average 20% to 30% above rival devices, which makes those outcomes all the more impressive as we work toward a differentiated, profitable leadership position in the category over time. In Italy we see added momentum, hitting nearly 20% offtake share among closed system pods, and Croatia shows fast movement too, within eight months of its launch; in the Czech Republic, rapid expansion has picked back up following a brief supply interruption early in the quarter that dragged on Q1 share. As of March 31, VEEV was on sale in seven markets, and more are slated to come this year, though the schedule depends on device supply. On a separate note, our renewed push to commercialize nicotine pouches under the Shiro name across the Nordics is moving along nicely, drawing favorable reactions from consumers. Shifting to sustainability and our ESG commitments, I'm glad to report two key items made public in our 2022 proxy statement. First, the Board of Directors revised the company's statement of purpose, widening it past smoke-free so it captures how wellness and healthcare fit into our strategy and transformation. Second, a tailored Sustainability Index now ties our ESG results directly to 30% of long-term compensation. More specifics will come in our Integrated Report on May 17, along with additional dedicated disclosures. The health impact of our products stays among our top ESG priorities, and rising adoption of smoke-free products globally is hastening the decline of cigarettes, as adult smokers move to less harmful options. Scientific and real-world proof keeps accumulating that smoke-free products carry substantial risk-reduction potential relative to smoking. Difficulties in certain markets are bound to arise, yet we keep backing regulatory and fiscal approaches that acknowledge how tobacco harm reduction policies can benefit public health. Italy offers a fresh illustration, having created separate excise tax categories for heatnot-burn, e-vapor and nicotine pouches. Thanks; I'll hand things back to Jacek now.

Jacek Olczak

executive
#7

Thank you, Emmanuel. Even with the difficulties we're facing in Russia and Ukraine, we've had a great beginning to this year — IQOS user growth has rebounded strongly, and the results so far from IQOS ILUMA, our truly pathbreaking innovation, have been outstanding. As we discussed not long ago at CAGNY, we hold a substantial pipeline of additional smoke-free innovations that will let us broaden and expand into both new and established categories and geographies. Our combustible segment is now holding category share steady, even with the cannibalization caused by IQOS, and that puts us in a position to speed up the shift of smokers toward better alternatives. We're also continuing to put money into long-term growth by creating innovative wellness and healthcare products, which aim to have a net positive effect on society. Our fundamentals for 2022 are solid, with a pro forma expectation of 4.5% to 6.5% organic net revenue growth and 9% to 11% currency-neutral adjusted diluted EPS growth. Even though substantial inflationary pressures and global supply chain disruption are hitting both the first half and the full year, we still anticipate that our organic operating income margin will expand by up to 100 basis points. Beyond that, in our reported guidance we've adopted the conservative assumption that Russia and Ukraine will contribute nothing further starting April 1. On the whole, we have a lot of confidence in the near- and mid-term growth outlook, and we stay dedicated to rewarding shareholders sustainably over time as our transformation continues. Thank you. We're now glad to take your questions.

Chris Growe

analyst
#8

Hi, good morning.

Jacek Olczak

executive
#9

Good morning.

Emmanuel Babeau

executive
#10

Hello, Chris.

Chris Growe

analyst
#11

Hello. If I may, I'd like to begin by asking about your IQOS outlook for this year and, clearly, the reduction tied to Russia and Ukraine. I simply want to confirm, when you consider it — the updated guidance factors in your projections without Russia and Ukraine, correct? Is that the sole change you've applied for volume, and does that revised figure of 88 billion to 92 billion sticks merely remove what you anticipated from Russia and Ukraine during this year?

Jacek Olczak

executive
#12

Right; for the whole year, we're only referring to volumes from Russia and Ukraine. Yet clearly, in Q1 we account for what was sold across both geographies, amounting to 5 billion. So on a pro forma basis for the entire year, excluding Russia and Ukraine, we're looking at 88 billion to 92 billion. However, should you add back that 5 billion already sold in the first period, the first quarter, that brings it straight to 93 billion-97 billion, which assumes, or is assuming, no additional IQOS sales starting April 1 in either Russia or Ukraine.

Chris Growe

analyst
#13

Understood. Thanks for that; next I was hoping to get some clarity regarding Q2. You mentioned that shipments of devices will be greater during that period. My sense is that this becomes a bigger engine for top-line expansion, while simultaneously certain timing issues—at least from what I gather in Japan—are going to drag on total revenue. From what I understand, you anticipate something along the lines of a low single-digit rise in revenue. So what I'd like to grasp, as far as you're able to assist, is how large each of those two elements actually is; my impression is that the Japan timing issue might be the bigger influence on 2Q revenue. Also, I want to get a handle on device supply. Does availability return to what I'd describe as complete device availability during the back half? And does that stem from units no longer designated for Russia and Ukraine, which frees up more supply for everyone else—could you make that clear? Thanks.

Jacek Olczak

executive
#14

Right. Okay. So when it comes to device shipments in Q1, on one hand, yes, you're completely correct, that helps contribute to stronger global revenue, but keep in mind those devices are exerting pressure on margins, correct. So that dynamic began between the devices and the effect on one hand on revenue and on margins. The major effect we anticipate for Q2 concerns the supply of consumable shipments. That means the heat sticks along with TEREA; consequently, among other supply chain constraints tied to halting investment in Russia, we must redirect that lost capacity toward our own sites, and that's going to take some time. As a result, we anticipate drawing down inventories further in Japan—primarily Japan—so that on the manufacturing side we'll have the right resourcing in place when we expect fairly robust growth on IMS, along with market share. And I believe, Emmanuel, on the slide has shown that we ought to consider we're targeting 24% — roughly a 24% market share for the quarter in Japan. So nothing is happening at the consumer level or the offtake level, but we have to carry out these inventory operations so we can get back to a normal shipment pattern in Q3 and Q4; and because of that, this will produce improved results and a more robust showing in the back half compared with the front half, which we estimate will be affected by the Q2 shipment difference. Now regarding the devices, I mean, there's ongoing sales of devices in the excluded geographies, correct. So it isn't the case that we halted selling—we halted recognizing this entire matter because of visibility and other factors, what's going on in Russia and Ukraine. But in practice, we at minimum need to maintain replacement devices, correct. The point isn’t simply that you can move volume away from Russia and Ukraine and send it somewhere else. In terms of device supplies, visibility has genuinely been improving, though it still isn’t perfect. Keep in mind that we were extremely careful about the second half of last year. Once order fulfillment improved and we gained clearer sight of future orders for this year, we became more confident about how we can capture—completely capture—the IQOS opportunity. So things look fine, not flawless, and I don’t want anyone to be misled: it isn’t flawless, yet it’s improved compared with, say, the start of the year. You also saw, when we had recovered some—and had nearly full-fledged availability of devices—how IQOS could speed up its growth in user acquisition and market share progression in Q1. So we know we have that capability, but all of it depends on supplies of both devices and heat sticks continuing without interruption.

Emmanuel Babeau

executive
#15

And Chris, perhaps to add to that, I believe it's truly crucial that everyone grasps how gross margin has moved across Q1, Q2, and H1 compared with H2. You surely recall that during last year, H1 gross margin stood at an exceptionally elevated level — we hit 70%. In H2, gross margin came in lower and was likely closer to a normal level. So what we observed in Q1 was, above all, going up against very tough comparables. As we've been laying out in the presentation, there are various drivers behind that 250 basis point decline in gross margin. For Q2, you should anticipate this factor persisting, given that the gross margin benchmark last year in Q2 was also 70%. Beyond that, we'll see even greater device sales than we did in Q1, which I view as encouraging since it demonstrates IQOS's success. We've raised air freight costs owing to the reasons we cited and the strain on the supply chain, and that will affect the margin. And the final factor is this mix, which — much like air freight, incidentally — is a temporary element, stemming from the fact that volumes for Japan will be reduced in Q2 alongside the recovery and the offsetting in H2; and because of that, you have the explanation for heightened pressure, gross margin pressure in Q2, but with the offsetting that will arrive in H2.

Jacek Olczak

executive
#16

Chris Growe speaking as the questioner: That was really helpful context. I appreciate it a lot. Then Pamela Kaufman, also asking a question: Hello there, and good morning.

Jacek Olczak

executive
#17

Morning to you as well.

Pamela Kaufman

analyst
#18

Regarding the 2023 outlook, how are you viewing next year's targets, especially for HTU? Should we expect a cut to your heated tobacco goal comparable to this year's guidance reduction of roughly 20%? Also, since Russia plays such a big part in the overall IQOS business, what changes are you making to your strategy so you can still hit the goal of 50% of revenue from smoke free products by 2025? Thank you.

Jacek Olczak

executive
#19

Thank you. We're still pursuing geographic and portfolio growth for IQOS both where we already operate and in new markets, and naturally we've had to deal with supply chain limitations and device availability, among other things. That's well understood by everyone. Perhaps a good way, or one way, to consider that 2023 target — I take it you mean the absolute volume goal for IQOS — is this: let's suppose, and this is the most conservative assumption you could make, that from April 1 onward we make no additional sales in Russia and Ukraine, and that basically represents the floor. Where does that leave us? I think everybody understands we need some time before we truly have full visibility into what's going on, what we'll do with our business, our plans regarding leaving Russia, and also whatever the longer-term picture might be for our Ukrainian operations and so on. There will be a range in absolute numbers, without a doubt. As I see the whole situation, it's possible we'll reach this target, though roughly 12 months late. In other words, I can't say — my view hasn't shifted regarding the target itself, I just acknowledge that perhaps a bit more time is needed to achieve it. Every other parameter stays the same as we've previously stated: the relative growth targets for top-line and bottom-line, plus the relative growth — or relative contribution, which is a very important target for us — of the non-combustible versus combustible business; on that front I'm confident we ought to be able to deliver. But when it comes to absolute volume, yes, we could fall short. Yet again, apologies for repeating myself, the way I see it, perhaps I need 12 more months in order to reach that same target through other geographies and organic growth in the markets where we already operate.

Emmanuel Babeau

executive
#20

Regarding your inquiry, Pamela, about the path to exceeding 50% in 2025: you have likely observed that during Q1, when calculated on a pro forma basis while leaving out Russia and Ukraine, our figure sits somewhat under the Group's complete perimeter—though only modestly so. Specifically, we stand at 30% compared with roughly 31%. Consequently, additional distance must indeed be bridged before reaching 50%. Nevertheless, considering the momentum evident in our IQOS operations alongside the prospect we have consistently demonstrated across low- and middle-income nations, we believe it is possible to close that gap and achieve this figure above 50%.

Pamela Kaufman

analyst
#21

Thank you; and next I have something to ask regarding the addition of new IQOS users. During this quarter you recorded a solid rebound, even after excluding the effect of Russia, amounting to 1 million users — more than 1 million users. Should we anticipate a comparable level of fresh user acquisition throughout the year? Also, what portion did ILUMA contribute to that, and might the supply interruption involving TEREA consumables have any effect? Did you catch what I asked?

Jacek Olczak

executive
#22

Yeah, I believe your inquiry was — apologies, since each of us truncated the sentence midway. What you asked was whether we can look forward to the same pattern of user acquisition moving ahead?

Pamela Kaufman

analyst
#23

Yes.

Jacek Olczak

executive
#24

All right. So listen, I'd say we saw over 1 million acquisitions during this quarter, and that reflects sequential growth compared with roughly 1 million acquisitions in Q4. What I mean is that this ties directly to how many devices we had available and having the complete range of devices. As you're aware, we now compete across various price tiers — we offer higher-priced devices, mid-priced devices, and cheaper devices. So provided we keep devices in stock, my view is we ought to match that same pace, or perhaps even exceed it, since you can tell from the conversion angle and from consumer preference as measured through NPS and other metrics that what we provide today is satisfying what consumers expect. That also connects in some way to the earlier questions: once we have clarity on device supply, correct, over the coming quarter or thereabouts, along with all the momentum we're able to generate beyond Russia and Ukraine, at that point we'd be able to update what we'll actually achieve a year from now regarding overall IQOS volume.

Pamela Kaufman

analyst
#25

Thank you.

Emmanuel Babeau

executive
#26

Thank you.

Vivien Azer

analyst
#27

Hi, good morning.

Jacek Olczak

executive
#28

Hi, good morning, Vivien.

Vivien Azer

analyst
#29

I'd like to ask a bit more about Japan. There are two remarks from you that I'm finding difficult to square. First, you mentioned that device mix was negative during the quarter, yet you also said device growth came from ILUMA. When we spoke three months ago, my understanding was that ILUMA's introduction added to mix in Japan, so is there something I've got wrong, or has something shifted? Thanks.

Jacek Olczak

executive
#30

Regarding the device mix, what I mean is that at this point we offer three iterations of IQOS ILUMA — a premium option, a mid option, and a lower-priced option, and that lower-priced one has only just reached consumers in the market. Naturally, when it comes to shipments, those were already present in Q1, since everything gets booked at the shipment level. And then there's the second point: this device — I mean ILUMA ONE, the cheapest one — carries an appealing price in the market, above what competitors charge, but appealing nonetheless, and below what we previously charged for that single version of IQOS 3. So perhaps that's something we need to dig into with Vivien.

Emmanuel Babeau

executive
#31

Yes, Vivien, if I can jump in here, this is Emmanuel. Within the device category, it's a favorable element in the mix, since it carries a higher price point. Yet any expansion in device revenue hurts the mix when you look at gross margin, because naturally it arrives with a far smaller gross margin compared with the consumables. So the greater the number of devices we move, the more you get some effect on revenue, and that effect is positive, but to be completely clear, it dilutes the gross margin rate.

Vivien Azer

analyst
#32

Got it. I believe the sales graph was the pricing tier, so thanks to you both for that. Turning to my second question, I was hoping for a bit more detail regarding Germany, where you saw substantial share gains, both versus last year and quarter over quarter. From an activation perspective, is there anything worth highlighting, since those results came in so strong?

Jacek Olczak

executive
#33

No, once again this stems from — we were in a post price increase, post price change situation in Germany, that's one factor; and the second is, once more, I'd say Germany began benefiting from no longer having restricted access to the devices. So once again this tracks the same narrative: we have continuous broad availability of the devices across a wide range. We're able to go into the portfolio once more, and that drives the performance. And there's one more remark I'd add here, Vivien: Germany is still operating with the IQOS free one version, which is a blade version, and that's the reason we went, for instance, to Switzerland with IQOS ILUMA ahead of opening the bigger market, which clearly will absorb a great deal of device volume — it's about how IQOS ILUMA would perform in a comparable sort of geography. So I'm very happy with the success IQOS ILUMA has had so far in Switzerland, particularly the German speaking part, since I used this as a — we could use this as the proxy for Germany when it comes to acceleration of the — further acceleration of growth in Germany; now, nothing in life is certain; but I think that's as much as we can infer from consumer reactions in Switzerland.

Vivien Azer

analyst
#34

Got it. Thanks so much.

Bonnie Herzog

analyst
#35

Okay. Thank you. Hello, everybody. I wanted to ask a few things about Russia, and I was hoping you might be able to give us, perhaps, a bit more granularity regarding your departure from that country and, really, how that process works mechanically. Could you help us grasp what is currently being produced in that market? Then, what about the volume that your St. Petersburg manufacturing site sends abroad? Could you tell us approximately what share of that volume goes to export? And then, where do you intend to perhaps move that volume, and on what timeline? And I suppose I'm just attempting to consider all of this in terms of whatever costs might come with it? And then, is that being captured in your guidance?

Jacek Olczak

executive
#36

Bonnie, this is Jacek. Just from how many specifics you listed in your question, you can see how complicated the circumstances are in Russia; so let's take them one at a time. Russia, in terms of what it has produced and exported until now, was not actually all that meaningful; we had far bigger intentions for growing Russia as one of the main suppliers of the new IQOS ILUMA, and therefore we decided to halt that investment right away, and because of that we put a temporary stop for the remainder of the market. Partly for the ILUMA launch in Russia, which we also called off, but beyond that Russia was meant to help supply the ILUMA consumables, which are HeatSticks, to other markets, Japan included. So our top priority is figuring out how to resource that capacity. Naturally, that capacity means equipment is installed in Russia; and we cannot — so we aren't using that equipment at present. What will become of that equipment later? We are also developing certain plans, but I'll leave it there and won't provide further specifics. Now, to leave Russia in an orderly way, we must first balance the interests of our shareholders and the employees in Russia. And you're aware that the constantly changing legislation in Russia creates substantial risk or limits on our ability to comply. And that's only within the context of a highly fluid regulatory landscape, both internationally — obviously the sanctions — and also the laws or legislation in Russia. So if we want to, we have a substantial presence in Russia, as everyone knows; we're in that market, and we built the business organically across the last 30 years. This is a 100% PMI International business. We have no partners involved in the core business; we are, of course, linked with local supply chains and wholesale and distribution elements. But PM Izhora and Philip Morris sales and distribution is a 100% Philip Morris business. We hold some shareholding on top of that, and we have a key distributor in that market alongside our major tobacco company. Taking apart, in a methodical way, every one of the strengths we hold in Russia is a complicated undertaking, yet we remain dedicated to seeing it through. So, when it comes to our guidance and the choices involved, we treat the PMI like the remainder of the business, which is performing extremely well in spite of all the headwinds we face and so forth, instead of letting it be muddied by something where our visibility and capacity to respond are constrained. So I realize my response hasn't provided you with any greater clarity, but that's the most we can offer right now. What I mean is, we are pursuing an exit, though it is presumably among the most intricate transactions in the history of the group, which we're drawing from the board.

Bonnie Herzog

analyst
#37

Yeah, that's hard to picture. Thanks for the detail. And so we're clear, on the exit side: is there a target date you can give us for a complete pullout from that market?

Jacek Olczak

executive
#38

Look, we'd prefer not to push it out any longer than we have to, provided we meet the needs of all the teams—or groups, if you will. And I'll say it again: we owe something to shareholders, yes, but we also owe something to the people we employ in Russia. Then there's the wider set of stakeholders, each with different expectations, and we're trying to solve for all of that in a way that leaves everyone satisfied—which is turning into a complicated task. Still, we're pushing nonstop on how to get this done. I'd note that if the business and our presence there were any other size, the picture might have been different. For us, though, this was a really large business.

Bonnie Herzog

analyst
#39

Honestly, that leads me right into my second question. When I consider the new pro forma HTU volume guidance you've given — 88 billion to 92 billion units for this year — it assumes 22% growth at the midpoint. What I'd like to get a handle on is the main drivers behind that, because the growth outlook now sits, I believe, above what you previously guided, yet Russia, as I understood it, was such a critical factor for that and for your future. So I simply want to grasp what's giving you that confidence, particularly on top of the uncertainty surrounding the semiconductor chip shortage situation? Thanks.

Jacek Olczak

executive
#40

Yes. Thank you. So clearly we have to make some, or are making some, assumptions regarding the supply chain, as I mentioned earlier. We don't have perfect visibility today across all the quarters left in this year. Still, I believe we possess sufficient confidence to put forward this pro forma estimate, or this pro forma guidance. Now, look, you can see that steady trajectory of IQOS expansion in basically every geography, even the ones that historically proved somewhat harder for us, where we did make progress but they weren't truly expanding at the group's rate, and at present we observe Japan, with that ILUMA, along with a few other markets where ILUMA is already present, experiencing a tremendous acceleration in growth. We're aware of what our plans hold for this going forward with ILUMA. We're also aware that IQOS < >, currently the device sold the most, remains highly appealing; and this persists even though we present our portfolio of both devices and consumables at a considerable premium compared to any other offers on the market. I believe we're gaining that confidence that IQOS will keep expanding, and we're also anticipating the point when its growth will speed up. Will IQOS in the near term, excluding Russia and Ukraine — sorry, the remaining geographies — offset the absence of Russia and Ukraine? I think across a longer stretch of time, we'll eventually see that, but over a shorter stretch it could prove somewhat difficult, okay. We aren't making any commitments at this point.

Bonnie Herzog

analyst
#41

Okay. Thank you.

Jacek Olczak

executive
#42

Thank you.

Nick Rolli

executive
#43

Gaurav, we’re not able to hear you. Would you mind asking that again?

Nick Rolli

executive
#44

Gaurav Jain asked whether that was clearer. Nick Rolli confirmed it was, and thanked him.

Gaurav Jain

analyst
#45

Apologies for that. My first question concerns your outlook for industry volume, plus your own volume excluding Russia and Ukraine; it appears things have improved. And when I look, particularly at European volumes, those look pretty robust. So we've got this kind of macro strain on consumers along with inflationary pressure, and Europe could be in recession, might not be in recession, oil price impact. So my question is, why are you observing stronger volumes? And is it that when cigarette prices historically rose 4 in Europe while wage growth was 1, so cigarettes became less affordable, and at present cigarette pricing remains 4 while wage inflation is probably 4 or 5, so cigarettes are in fact becoming more affordable, and that's the reason you're seeing better volume trends?

Jacek Olczak

executive
#46

Well, I think we should — I mean, we have the information of Q1 that are pointing to this evolution. It is true, Gaurav, that there are no uncertainty on what's going to be the growth of the global economy in the coming quarters. I suppose there is some trend in the market that our underlying trends in term of demographics and behaviors. Let's face it there is also still the contribution of rebound after the COVID. So last year was not a normal year, we are becoming much more normal. I'm not saying we're there yet. I mean, in Duty Free, we're not. But in other markets, we can hope that for the coming months to be more normal and that's going to be a positive; so I don't know what's going to be the impact of a potential slowdown of the economy. By the way, we're going to have an impact on volume or more on downtrading and some countries in consumer going for cheaper offering. Today what we see and we've been highlighting that is Marlboro recovering market share and we see Chesterfield being very successful and we see of course great success with all our IQOS brands. So that is what is driving for us this outlook for growth in volume; and of course, starting Q1 with a very nice growth, even if we flag the fact that there were some — maybe some anticipation, but I think that the Q1 numbers are there; it shows the dynamism that we are seeing in our portfolio.

Gaurav Jain

analyst
#47

Sure; and turning to the EPS guidance and the dividend. So your dividend payout ratio is going to be above 90% now; so what effect does that have on how you're considering buybacks? And we continue to witness these cycles with PM every 3 years, you get huge adverse FX and if we look back 10 years, the euro was at €150, the yen was at JPY70, then we had a cycle in 2014 and 2017. Now we have another FX cycle; and clearly many of your costs are denominated in Swiss franc and dollar. So can you do something so that the cost mismatch, the transaction FX mismatch is smaller? And we once again end up in a situation where the dividend payout ratio is getting very tight.

Jacek Olczak

executive
#48

Well, Gaurav, so yes, of course based on the guidance we've been providing, we would have a payout ratio that would rise considerably compared to 2021. I think we've demonstrated previously, the ability to grow profit over time and bring that down. Our goal to decrease it over time and we didn't provide any kind of precise target to go down to 75% is still there. I agree that given the adverse event we are facing, it's going to take somewhat more time to reach that; that's true, not so much, I mean, the currency is a factor, but it's really the buildup of currency and Russia exiting the perimeter of the group that is causing that situation. Now on the ForEx there are 2 elements. One is the pressure on margin and we keep working on trying to balance better the currency in which we're investing and the currency in which we have our cost. We do that with the supply chain. There are some limitations, because there are a number of things that you purchase in dollar, of course, we do that through everything we buy. But there is one element that we kind of can't change which is that we have limited invoicing in dollar. So when the dollar is rising versus most of the currency that is an impact, which is mechanical and on which there isn't much we can do. So we can work and I think we continue to work on the margin dimension. We cannot work on the fact that we have limited invoicing.

Gaurav Jain

analyst
#49

Sure. Thanks a lot.

Jacek Olczak

executive
#50

Thank you.

Nick Rolli

executive
#51

Owen, is there anything you'd like to ask?

Jared Dinges

analyst
#52

Hello everyone. I simply wanted to inquire about how pricing is shaping up, since inflation in certain markets such as Europe has climbed to heights unseen in quite a while. Considering that you're also observing cost inflation worldwide, particularly after Russia and Ukraine, do you believe there might be a greater chance to implement further price hikes? Perhaps we could witness a somewhat larger margin offset.

Jacek Olczak

executive
#53

We are implementing both a price increase and a price variance. So the start of the — turned out stronger than our original expectations. We'll find out what the rest of the year, and particularly the second half, holds. Regarding inflation, we must also examine what the inflation on materials looks like. That is, things like the cost of living versus what income inflation looks like, correct? Since at the concept level, we have not yet observed inflation at the income level. So we need to locate the proper point at the proper balance for where we step in. Yet across most geographies, I would describe the pricing environment as turning favorable. I mean, Emmanuel, mention Indonesia. Conversely, we're experiencing a very robust volume rebound in Indonesia; and with luck, Indonesia too — which was once a fairly important, significant contributor to pricing — will with luck, near the close of this year or certainly in 2023, bring back that pricing contribution. We had a price increase in Germany working its way through the market, plus the Philippines, Turkey, okay. Now Turkey moves to hyper-inflationary accounting; we're attempting to price it broadly, considering inflation as the pressure. But as I mentioned, at the start of the year we already began with pricing variance ahead of our own expectations; so let's see how this carries on through the year.

Jared Dinges

analyst
#54

Understood. And perhaps as a quick follow-up regarding Southeast Asia, it's obviously been a really robust beginning to the year when it comes to volumes — what do you anticipate for volumes over the remainder of the year?

Jacek Olczak

executive
#55

Well, there's this ongoing — bear in mind this is a region of the world that, sadly, still hasn't emerged from COVID, correct? So things really haven't returned to how they were before COVID. I think some underlying growth possibilities exist simply because, should they keep bouncing back from the COVID situation, we ought to begin witnessing steadily improving volumes; and like I mentioned, we implemented a price rise in the Philippines, we're putting through some pricing, we're pushing pricing somewhat faster in Indonesia, yet conversely, we remain in the — as you'll recall, Indonesia is taking a few roughly steps of a price hike to pass along the start of the excise rise. So we still require a bit more time before reaching the net margin improvement space. But it largely comes down, to put it briefly, to sustained recovery and no additional surprises when it comes to COVID.

Emmanuel Babeau

executive
#56

And Jared, like we mentioned, we're anticipating a good revenue increase in the region during this year, which would represent a really positive development.

Jared Dinges

analyst
#57

That’s correct. Thanks, guys.

Emmanuel Babeau

executive
#58

Thank you.

Nick Rolli

executive
#59

Thank you; that was the last question, operator.

Nick Rolli

executive
#60

I think Jacek had some closing remarks.

Jacek Olczak

executive
#61

Alright, I appreciate all of you being here and staying with us, and this quarter turned out to be quite involved and difficult for our company, and because of certain technical issues, this earnings call likewise cannot really be tailored to what happened during the quarter. There's one remark I want to make to everybody, and I'm hoping you're still connected. I'd like to use this moment to express gratitude to Mr. Nick Rolli for his remarkable service to PMI and to our former parent company across the last 35 years, and especially in his capacity as Vice President, Investor Relations starting with the 2008 Philip Morris International. As all of you, I believe, would concur with me, he has played an essential part throughout our company's journey. And I'm aware that you, our investors and analysts, will join me in offering Nick congratulations and in wishing him the very best for a retirement he so richly deserves. At the same time, I'd also like to congratulate James Bushnell on his new role — I have a particular pleasure here, because I personally was the one who hired Mr. Bushnell into PMI for his new role as the successor to Nick Rolli — and I believe he will get the same backing and welcome that Nick Rolli has had from all of you over the last 35 years. So welcome, James, and thank you, Nick.

Nick Rolli

executive
#62

Appreciate that, Jacek. Thanks to you as well, Emmanuel. Nice work, James. I want to thank everyone joining this call, since I know several of you and I go back a long way, and that connection matters to me — I'm genuinely grateful. That wraps things up for today. Also, my apologies for the technical problems during my previous call; we will get it all sorted out and I'm glad to take on whatever follow-up questions you have. Many thanks to all of you.

Jacek Olczak

executive
#63

See you soon, guys. Thank you.

Operator

operator
#64

That brings us to the end of today's program. We appreciate you taking part. You're welcome to disconnect whenever you like.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.